A Novel hAPP/htau Mouse Model of Alzheimer's Disease: Inclusion of APP With Tau Exacerbates Behavioral Deficits and Zinc Administration Heightens Tangle Pathology
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The brains of those with Alzheimer’s disease have amyloid and tau pathology; thus, mice modeling AD should have both markers. In this study, we characterize offspring from the cross of the J20 (hAPP) and rTg4510 (htau) strains (referred to as dual Tg). Behavior was assessed at both 3.5 and 7 months, and biochemical differences were assessed at 8 months. Additionally, mice were placed on zinc (Zn) water or standard lab water in order to determine the role of this essential biometal. Behavioral measures examined cognition, emotion, and aspects of daily living. Transgenic mice (dual Tg and htau) showed significant deficits in spatial memory in the Barnes Maze at both 3.5 and 7 months compared to controls. At 7 months, dual Tg mice performed significantly worse than htau mice (p < .01). Open field and elevated zero maze (EZM) data indicated that dual Tg and htau mice displayed behavioral disinhibition compared to control mice at both 3.5 and 7 months (p < .001). Transgenic mice showed significant deficits in activities of daily living, including burrowing and nesting, at both 3.5 and 7 months compared to control mice (p < .01). Dual Tg mice built very poor nests, indicating that non-cognitive tasks are also impacted by AD. Overall, dual Tg mice demonstrated behavioral deficits earlier than those shown by the htau mice. In the brain, dual Tg mice had significantly less free Zn compared to control mice in both the dentate gyrus and the CA3 of the hippocampus (p < .01). Dual Tg mice had increased tangles and plaques in the hippocampus compared to htau mice and the dual Tg mice given Zn water displayed increased tangle pathology in the hippocampus compared to htau mice on Zn water (p < .05). The dual Tg mouse described here displays pathology reminiscent of the human AD condition and is impaired early on in both cognitive and non-cognitive behaviors. This new mouse model allows researchers to assess how both amyloid and tau in combination impact behavior and brain pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268 · cited 1×
“Barnes Maze Hippocampal-dependent tasks are important in Tg animal studies because the HP is affected by AD pathology (Hyman et al., 1984; Braak and Braak, 1991; Serrano-Pozo et al., 2011; Halliday, 2017) and deficits in spatial memory are fairly robust.”
BackgroundTau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 6×
“Certain hAPP/tau mice such as the JNPL3 × Tg2576 cross (Lewis et al., 2001) and the APP23/B6P301L (Bolmont et al.”
BackgroundInfluentialControl of memory formation through regulated expression of a CaMKII transgene
Mayford, M., Bach, M. E., Huang, Y.-Y., Wang, L., Hawkins, R. D., & Kandel, E. R. (1996) · Science · doi:10.1126/science.274.5293.1678 · Cited by 1,550 · cited 1×
“In order for tau to be expressed in this model, mice must contain both the transgene of interest (Tau P301L) as well as the CaMKIIa promoter under the regulation of the tetracycline-controlled transactivator (tTA) which drives and restricts expression of tau in the forebrain (Mayford et al., 1996; Ramsden et al., 2005…”
BackgroundSoluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“Studies utilizing Thioflavin-S to detect plaque pathology have often revealed bright centers in histochemically marked plaques (Lue et al., 1999; Chishti et al., 2001); in the current study, we did not see this type of reactivity.”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 2×
“The interaction of amyloid and tau has been hypothesized to be an essential aspect of AD (Götz et al., 2001; Lewis et al., 2001; Hurtado et al., 2010).”
BackgroundRapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 1×
“Zinc in particular is a metal of interest for those studying AD, as increases in Zn2+ are seen in Aβ plaques and Zn interacts with Aβ peptides (Bush et al., 1994; Barnham and Bush, 2014).”
BackgroundChronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 1×
“A separate measure of depressive-like behavior, or anhedonia may be better suited for future studies with this new mouse, such as the saccharin-preference test (Willner et al., 1992).”
MethodTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“In addition, drug research focusing on Aβ has consistently failed to produce significant clinical findings (Doig et al., 2017; Honig et al., 2018), leading to no new drugs on the market since the early 2000s.”
BackgroundAugustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 1×
“AT8 has been seen to primarily detect extracellular neurofibrillary tangles (Augustinack et al., 2002).”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 1×
“Studies utilizing Thioflavin-S to detect plaque pathology have often revealed bright centers in histochemically marked plaques (Lue et al., 1999; Chishti et al., 2001); in the current study, we did not see this type of reactivity.”
BackgroundRamsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 1×
“In order for tau to be expressed in this model, mice must contain both the transgene of interest (Tau P301L) as well as the CaMKIIa promoter under the regulation of the tetracycline-controlled transactivator (tTA) which drives and restricts expression of tau in the forebrain (Mayford et al., 1996; Ramsden et al., 2005…”
BackgroundEarly Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497 · cited 1×
“Zinc in particular is a metal of interest for those studying AD, as increases in Zn2+ are seen in Aβ plaques and Zn interacts with Aβ peptides (Bush et al., 1994; Barnham and Bush, 2014).”
BackgroundAmyloid toxicity in Alzheimer’s disease
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselman, L. J. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0063 · Cited by 447
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · cited 1×
“Amyloid increases tau phosphorylation (Lloret et al., 2011; Nisbet et al., 2015),”
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284 · cited 1×
“The use of metal protein attenuating compounds, clioquinol (CQ) (White et al., 2006) and PBT2 have been used to try and reverse this situation; clinical trials utilizing PBT2 and CQ have led to some significant improvements in cognition (Adlard and Bush, 2018).”
Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281 · cited 3×
“Examples of mouse models modeling both amyloid and tau pathology include the Tg2576/JNPL3 cross (Lewis et al., 2001), crosses of the Tg2576 and VLW(tau) mice (Pérez et al., 2005; Ribé et al., 2005), hAPP (Swe)/wildtype human Tau (Chabrier et al., 2014), hAPPNLI/Tau(P301L) (Paulson et al., 2008), APP23/B6P301L (Bolmont…”
BackgroundTakeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021050 · Cited by 247 · cited 3×
“The rTg4510 mouse has not been assessed in the FS test previously; however, a study using the P301S tau mouse, found decreased immobility (Takeuchi et al., 2011), consistent with the results shown here.”
BackgroundResultImmune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease
Vehmas, A. K., Kawas, C. H., Stewart, W. F., & Troncoso, J. C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00090-8 · Cited by 230 · cited 2×
“, 2010) and to be higher in human AD brains compared to controls (Vehmas et al., 2003; Ingelsson et al., 2004) and astrocytes surround plaques in the AD brain (Vehmas et al.”
BackgroundHurtado, D. E., Molina-Porcel, L., Iba, M., Aboagye, A. K., Paul, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100346 · Cited by 222 · cited 1×
“The interaction of amyloid and tau has been hypothesized to be an essential aspect of AD (Götz et al., 2001; Lewis et al., 2001; Hurtado et al., 2010).”
BackgroundKitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178 · cited 1×
“Tau mouse models have helped characterize the dysfunction that NFTs can have on mouse behavior and cellular processes, even though in AD no mutation in tau directly leads to the disease (Kitazawa et al., 2012).”
BackgroundLeroy, K., Ando, K., Laporte, V., Dedecker, R., Suain, V., Authelet, M., Héraud, C., Pierrot, N., Yilmaz, Z., Octave, J.-N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.012 · Cited by 161
The Role of Zinc in Alzheimer′s Disease
Watt, N. T., Whitehouse, I. J., & Hooper, N. M. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/971021 · Cited by 148 · cited 6×
“The His residues of Aβ plaques bind Zn2+ (Watt et al., 2010; Leal et al., 2012) and key cysteine (Cys) residues in tau can bind Zn2+ directly (Mo et al.”
BackgroundInfluentialXiong, Y., Jing, X.-P., Zhou, X.-W., Wang, X.-L., Yang, Y., Sun, X.-Y., Qiu, M., Cao, F.-Y., Lu, Y.-M., Liu, R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.07.003 · Cited by 122
Filali, M., & Lalonde, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.066 · Cited by 121 · cited 1×
“, 2018), APPswe/PS1 mice (Filali and Lalonde, 2009), and both CRND8 and CRND8/APOEe4 mice (Graybeal et al.”
BackgroundHan, H. J., Allen, C. C., Buchovecky, C. M., Yetman, M. J., Born, H. A., Marin, M. A., Rodgers, S. P., Song, B. J., Lu, H.-C., Justice, M. J., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0893-12.2012 · Cited by 105 · cited 2×
“, 2008) and the background of the mice can impact behavioral changes in mice expressing the promoter (McKinney et al., 2008; Han et al., 2012).”
BackgroundChabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., & LaFerla, F. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.007 · Cited by 97
Cited by
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Stefanescu, R., Stanciu, G. D., Luca, A., Paduraru, L., & Tamba, B.-I. (2020) · Biomolecules · doi:10.3390/biom10060870 · Cited by 35
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Metadata
- Authors
- Lippi, S. L. P., Smith, M. L., & Flinn, J. M.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-11-22
- Volume
- 10
- Pages
- 382-382
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2901070508
- Cited by
- 36
- References
- 36
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.